Ionis Pharmaceuticals (LTS:0JDI) Cyclically Adjusted FCF per Share: $-0.68 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JDI Ionis Pharmaceuticals Inc LTS:0JDI
71 GF Score
Price $56.98
GF Value $53.91
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Cyclically Adjusted FCF per Share?

Ionis Pharmaceuticals LTS:0JDI -3.22% 71 Cyclically Adjusted FCF per Share is $-0.68 as of Mar. 2026. GuruFocus rates LTS:0JDI with a GF Score™ of 71/100 and a GF Value™ of $53.91 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-4.950. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.68 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ionis Pharmaceuticals was 84.20% per year. The lowest was -17.40% per year. And the median was 9.40% per year.

As of today (2026-07-14), Ionis Pharmaceuticals's current stock price is $56.9795. Ionis Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.68. Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Ionis Pharmaceuticals was 5829.00. The lowest was 39.84. And the median was 113.72.


Ionis Pharmaceuticals  (LTS:0JDI) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Ionis Pharmaceuticals was 5829.00. The lowest was 39.84. And the median was 113.72.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.57 0.31 -0.05 -0.27

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.09 -0.22 -0.27 -0.68

LTS:0JDI vs EXEL, BBIO, AXSM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


LTS:0JDI
71GF Score
Ionis Pharmaceuticals Inc LTS:0JDI
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-4.95/330.2130*330.2130
=-4.950

Current CPI (Mar. 2026) = 330.2130.

Ionis Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.316 241.018 -0.433
201609 0.179 241.428 0.245
201612 -0.253 241.432 -0.346
201703 0.948 243.801 1.284
201706 -0.036 244.955 -0.049
201709 0.072 246.819 0.096
201712 0.105 246.524 0.141
201803 0.080 249.554 0.106
201806 3.826 251.989 5.014
201809 -0.224 252.439 -0.293
201812 0.784 251.233 1.030
201903 0.731 254.202 0.950
201906 -0.231 256.143 -0.298
201909 -0.213 256.759 -0.274
201912 1.460 256.974 1.876
202003 -0.126 258.115 -0.161
202006 -0.398 257.797 -0.510
202009 -0.166 260.280 -0.211
202012 0.651 260.474 0.825
202103 -0.410 264.877 -0.511
202106 -0.489 271.696 -0.594
202109 -0.426 274.310 -0.513
202112 1.414 278.802 1.675
202203 -0.248 287.504 -0.285
202206 -0.159 296.311 -0.177
202209 -0.222 296.808 -0.247
202212 -1.445 296.797 -1.608
202303 -1.021 301.836 -1.117
202306 -0.772 305.109 -0.836
202309 -0.783 307.789 -0.840
202312 0.229 306.746 0.247
202403 -1.070 312.332 -1.131
202406 -0.960 314.175 -1.009
202409 -0.749 315.301 -0.784
202412 -0.913 315.605 -0.955
202503 -1.033 319.799 -1.067
202506 0.752 322.561 0.770
202509 -0.866 324.800 -0.880
202512 -0.988 324.054 -1.007
202603 -4.950 330.213 -4.950

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.68 mean?
Ionis Pharmaceuticals (LTS:0JDI) has a Cyclically Adjusted FCF per Share of $-0.68 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Ionis Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-0.68. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Cyclically Adjusted FCF per Share compare to EXEL and BBIO?
Ionis Pharmaceuticals' Cyclically Adjusted FCF per Share of $-0.68 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Fairly Valued. The stock's GF Value™ is $53.91, compared to a current price of $56.98 — trading 5.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.68. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Cyclically Adjusted FCF per Share is $-0.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $56.98 is trading 5.7% above its estimated GF Value™ of $53.91. GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0JDI:

  • Cyclically Adjusted FCF per Share: $-0.68
  • GF Value™: $53.91 vs. price of $56.98 (5.7% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score

Get the complete analysis for LTS:0JDI

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.98
Price
$53.91
GF Value